Intellectual Property India Publishes Patent Application for Preclinical Antiparkinsonian Drug Evaluation Model Using Genetically Tremor-Exhibiting Columba Livia Domestica

MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202631027134 A) filed by Majumdar, Dr. Mrityunjoy; Samanta, Dr. Arnab; Roy, Mr. Sourav; Roy, Mr. Prodip; and Manna, Mrs. Mahuya Majumdar on March 08, 2026, for Preclinical Antiparkinsonian Drug Evaluation Model Using Genetically Tremor-Exhibiting Columba Livia Domestica.

Inventors include Majumdar, Dr. Mrityunjoy; Samanta, Dr. Arnab; Roy, Mr. Sourav; Roy, Mr. Prodip; Mamud, Mr. Rahaman Mehedi; Pramanick, Mr. Krishanu; Nandi, Mr. Debajyoti; Prasad, Mr. Mohit Kumar; Dakshi, Mr. Sumit; Datta, Mr. Kundan; Naskar, Mr. Sohan; Farhin, Ms. Kazi; Debnath, Mr. Abhik; Bhunia, Mr. Ishan; Manna, Mr. Mrinmoy; Sardar, Mr. Pranay; Karar, Mr. Shribus; Roy, Mr. Sayantan Singha; Manna, Ms. Ruchismita; Chanda, Mr. Arpan; Paul, Mr. Subhajit; Basu, Mr. Tamal; Banerjee, Ms. Riddhita; Sarkar, Mr. Soumyadeep; and Maiti, Mr. Anish.

The application for the patent was published on July 10, 2026, under issue no. 28/2026.

Abstract: The present invention relates to a preclinical experimental method (100) for evaluating pharmacological activity of candidate antiparkinsonian agents using genetically tremor-exhibiting Columba livia domestica, particularly Mookee pigeons. The method comprises selecting (102) one or more healthy adult pigeons exhibiting naturally occurring genetically expressed tremor, maintaining (104) the pigeons under predetermined environmental conditions, recording (106) an individual baseline tremor frequency, administering (108) a candidate antiparkinsonian agent, recording (110) post-administration tremor activity, determining (112) a post- administration tremor frequency, comparing (114) the post-administration tremor frequency with the baseline tremor frequency, and determining (116) pharmacological activity based on reduction in tremor frequency. The naturally occurring tremor serves as a physiological surrogate marker, enabling pharmacological evaluation without inducing Parkinsonian symptoms using neurotoxic chemicals or invasive procedures and without requiring sacrifice of the experimental animal, thereby providing a cost-effective, reproducible and ethically improved preclinical drug evaluation model.

Disclaimer: Curated by HT Syndication.